5 years ago

Immunocore Secures $130 Million in Series B Funding for Cancer and Autoimmune Disease Therapies

  • Immunocore, a UK-based clinical-stage T cell receptor biotechnology company, raised over $130 million in Series B financing

  • The round was led by General Atlantic, with participation from CCB International, JDRF T1D Fund, Rock Springs Capital, Terra Magnum Capital Partners and WuXi AppTec’s Corporate Venture Fund, as well as Eli Lilly and Company and RTW Investments, and the Bill & Melinda Gates Foundation through conversion of its outstanding loan note

  • The company intends to use the funds to expand and accelerate its clinical stage pipeline of ImmTAX™ molecules, which includes three oncology programs in MAGE-A4, NYESO-1, and tebentafusp (IMCgp100), as well as programs for chronic Hepatitis B and PRAME

  • Immunocore is also developing a platform to treat autoimmunity, including type one diabetes.

      • ProblemHealthcare

      "Patients with cancer, infection, and autoimmune disease are in desperate need for new and effective treatments."

      Solution

      "Immunocore develops and commercializes a new generation of medicines that use T cell receptors to target specific cells in the body. This approach can help to fight cancer, infection, and autoimmune disease."

      Covered on